NCT00859469 · FLOW

Participant flow

Eloxatin® Plus Gemcitabine Chemotherapy for Mesothelioma · Source last updated 2019-10-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
The study drugs will be administered in the following manner: Gemcitabine, at 1000 mg/m² IV infusion over 90 minutes, then Oxaliplatin, at 100 mg/m² IV infusion over 2 hours.
id
FG000
title
Oxaliplatin and Gemcitabine

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
2
type
Adverse Event
reasons
group Id
FG000
num Subjects
9
type
Lack of Efficacy
reasons
group Id
FG000
num Subjects
1
type
Withdrawal by Subject
reasons
group Id
FG000
num Subjects
16
type
Death
milestones
achievements
group Id
FG000
num Subjects
29
type
STARTED
achievements
group Id
FG000
num Subjects
16
type
6 Cycles
achievements
group Id
FG000
num Subjects
1
type
COMPLETED
achievements
group Id
FG000
num Subjects
28
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

Patients who are deemed eligible will start the treatment cycle, defined as an interval of 14 days, and comprising of treatment with Gemcitabine followed immediately by Oxaliplatin.

recruitment Details

Patients will be screened using standard health care assessments and tests. All of these tests must be done within 4 weeks before patients begin treatment.

Complete source fields